CD40LG and agammaglobulinemia: This degree of secondary antibody deficiency is higher than observed for the long-term combination of rituximab and methotrexate in rheumatoid arthritis, where reduced levels of IgG, IgA, and IgM were observed in 3.5, 1.1, and 22.4% of patients, respectively (128).